Chemical combination effects predict connectivity in biological systems

Molecular Systems Biology

Volumn 3, Issue , 2007, Pages

  Lehár, Joseph ^a,b   Zimmermann, Grant R ^a   Krueger, Andrew S ^b   Molnar, Raymond A ^a   Ledell, Jebediah T ^a   Heilbut, Adrian M ^a   Short III, Glenn F ^a   Giusti, Leanne C ^a   Nolan, Garry P ^a   Magid, Omar A ^a   Lee, Margaret S ^a   Borisy, Alexis A ^a   Stockwell, Brent R ^c   Keith, Curtis T ^a  

^a Department of Preclinical Development and Formulations   (United States)

^b BOSTON UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Chemical genetics; Combinations and synergy; Metabolic and regulatory networks; Simulation and data analysis

Indexed keywords

ARTICLE; BIOLOGY; DISEASE MODEL; GENETICS; HUMAN; MUTAGENESIS; PREDICTION; PRIORITY JOURNAL; SCREENING; SIMULATION; TUMOR; YEAST; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL STRAIN HCT116; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; SACCHAROMYCES CEREVISIAE; STATISTICAL MODEL; SYSTEMS BIOLOGY; VALIDATION STUDY;

STEROL;

COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, FUNGAL; HCT116 CELLS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; SACCHAROMYCES CEREVISIAE; STEROLS; SYSTEMS BIOLOGY;

EID: 33847643207     PISSN: 17444292     EISSN: 17444292     Source Type: Journal    
DOI: 10.1038/msb4100116     Document Type: Article

References (62)

1. Ashford JR, Cobby JM (1974) A system of models for the action of drugs applied singly or jointly to biological organisms. Biometrics 30: 11-31
2. Awwad RA, Sergina N, Yang H, Ziober B, Willson JK, Zborowska E, Humphrey LE, Fan R, Ko TC, Brattain MG, Howell GM (2003) The role of transforming growth factor alpha in determining growth factor independence. Cancer Res 63: 4731-4738
3. Berenbaum MC (1985) The expected effect of a combination of agents: the general solution. J Theor Biol 114: 413-431
4. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93-141
5. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373: 231-241
6. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26: 585-615
7. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehár J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100: 7977-7982
8. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G (2004) A physical and functional map of the human tnf-alpha/nf-kappa b signal transduction pathway. Nat Cell Biol 6: 97-105
9. Carter Jr WH, Wampler GL (1986) Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treat Rep 70: 133-140
10. Chou T-C, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454
11. Csermely P, Ágoston V, Pongor S (2004) The efficiency of multi-target drugs: the network approach might help drug design. arXiv 1-9. http://arxiv.org/abs/q-bio.MN/041204
12. Davidson EH, Rast JP, Oliveri P, Ransick A, Calestani C, Yuh CH, Minokawa T, Amore G, Hinman V, Arenas-Mena C, Otim O, Brown CT, Livi CB, Lee PY, Revilla R, Rust AG, Pan Z, Schilstra MJ, Clarke PJ, Arnone MI, Rowen L, Cameron RA, McClay DR, Hood L, Bolouri H (2002) A genomic regulatory network for development. Science 295: 1669-1678
13. Davis PD, Elliott LH, HarrisW, Hill CH, Hurst SA, Keech E, Kumar MK, Lawton G, Nixon JS, Wilkinson SE (1992) Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem 35: 994-1001
14. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB (1997) Identification of the fks1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 41: 2471-2479
15. Elena SF, Lenski RE (1997) Test of synergistic interactions among deleterious mutations in bacteria. Nature 390: 395-398
16. Ermentrout GB (2002) Simulating, Analyzing, and Animating Dynamical Systems: A Guide to xppaut for Researchers and Students. Philadelphia, PA: Society for Industrial & Applied Mathematics
17. Famili I, Forster J, Nielsen J, Palsson BO (2003) Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network. Proc Natl Acad Sci USA 100: 13134-13139
18. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) Idenfification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632
19. Filliben JJ (2005) Exploratory data analysis. Engineering Statistics Handbook, Internet, National Institute of Standards and Technology http://www.itl.nist.gov/div898/handbook/eda/section3/eda356.htm
20. Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22: 7512-7523
21. Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Pazhanisamy S, Fleming MA, Galullo V, Su MSS, Wilson KP (1998) A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci 7: 2249-2255
22. Gardner RG, Shan H, Matsuda SP, Hampton RY (2001) An oxysterol-derived positive signal for 3-hydroxy- 3-methylglutaryl-CoA reductase degradation in yeast. J Biol Chem 276: 8681-8694
23. Giaever G, Flaherty P, KummJ, Proctor M, NislowC, Jaramillo DF, Chu AM, Jordan MI, Arkin AP, Davis RW (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci USA 101: 793-798
24. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385
25. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199: 93-98
26. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999
27. Haggarty SJ, Clemons PA, Schreiber SL (2003) Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J Am Chem Soc 125: 10543-10545
28. Harrap KR, Jackson RC (1975) Enzyme kinetics and combination chemotherapy: an appraisal of current concepts. Adv Enzyme Regul 13: 77-96
29. Hartman IV JL, Tippery NP (2004) Systematic quantification of gene interactions by phenotypic array analysis. Genome Biol 5: R49
30. Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P, Bennett K, Boutilier K, Lang L, Wolting C, Donaldson I, Schandorff S, Shewnarane J, Vo M, Taggart J, Goudreault M, Muskat B, Alfarano C, Dewar D, Lin Z, Michalickova K, Willems AR, Sassi H, Nielsen PA, Rasmussen KJ, Andersen JR, Johansen LE, Hansen LH, Jespersen H, Podtelejnikov A, Nielsen E, Crawford J, Poulsen V, Sorensen BD, Matthiesen J, Hendrickson RC, Gleeson F, Pawson T, Moran MF, Durocher D, Mann M, Hogue CW, Figeys D, Tyers M (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415: 180-183
31. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH (2000) Functional discovery via a compendium of expression profiles. Cell 102: 109-126
32. Ideker T, Galitski T, Hood L (2001) A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2: 343-372
33. Jackson RC (1993) Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Cancer Res 53: 3998-4003
34. Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 1-8
35. Kishony R, Leibler S (2003) Environmental stresses can alleviate the average deleterious effect of mutations. J Biol 2: 14
36. Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 102: 9714-9719
37. Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA (2002) Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298: 799-804
38. Loewe S (1928) Die quantitativen probleme der pharmakologie. Ergebn Physiol 27: 47-187
39. Lorenz RT, Parks LW(1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 34: 1660-1665
40. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137
41. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Bio 2: 329-337
42. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U (2002) Network motifs: simple building blocks of complex networks. Science 298: 824-827
43. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M (1994) Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phospatidylinositol 3-kinase. J Biol Chem 269: 3563-3567
44. Ozier O, Amin N, Ideker T (2003) Global architecture of genetic interactions on the protein network. Nat Biotechnol 21: 490-491
45. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22: 62-69
46. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ (2004) Multidimensional drug profiling by automated microscopy. Science 306: 1194-1198
47. Press WH, Teukolsky SA, Vetterling WT, Flannery BP (1997) Numerical Recipes in c: The Art of Scientific Computing, 2nd edn. Cambridge: CUP
48. Rine J, HansenW, Hardeman E, Davis RW(1983) Targeted selection of recombinant clones through gene dosage effects. Proc Natl Acad Sci USA 80: 6750-6754
49. Schlessinger J (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507
50. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 20: 370-375
51. Segrè D, Deluna A, Church GM, Kishony R (2005) Modular epistasis in yeast metabolism. Nat Genet 37: 77-83
52. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated ki-ras. Science 260: 85-88
53. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M (2006) Biogrid: a general repository for interaction datasets. Nucleic Acids Res 34 (Database issue): D535-D539
54. Terrell CL, Hughes CE (1992) Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 67: 69-91
55. Tong AH, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL, Chang M, Chen Y, Cheng X, Chua G, Friesen H, Goldberg DS, Haynes J, Humphries C, He G, Hussein S, Ke L, Krogan N, Li Z, Levinson JN, Lu H, Menard P, Munyana C, Parsons AB, Ryan O, Tonikian R, Roberts T, Sdicu AM, Shapiro J, Sheikh B, Suter B, Wong SL, Zhang LV, Zhu H, Burd CG, Munro S, Sander C, Rine J, Greenblatt J, Peter M, Bretscher A, Bell G, Roth FP, Brown GW, Andrews B, Bussey H, Boone C (2004) Global mapping of the yeast genetic interaction network. Science 303: 808-813
56. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F (1991) The bisindolylmaleimide gf 109203x is a potent and selective inhibitor of protein kinase C. J Biol Chem 266: 15771-15781
57. Warringer J, Ericson E, Fernandez L, Nerman O, Blomberg A (2003) High-resolution yeast phenomics resolves different physiological features in the saline response. Proc Natl Acad Sci USA 100: 15724-15729
58. Wills EA, Redinbo MR, Perfect JR, Del Poeta M (eds) (2000) New Potential Targets for Antifungal Development. Expert opinion on therapeutic targets. London: Ashley
59. Yano H, Agatsuma T, Nakanishi S, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y (1995) Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. Biochem J 312: 145-150
60. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38: 489-494
61. Zhang LV, King OD, Wong SL, Goldberg DS, Tong AH, Lesage G, Andrews B, Bussey H, Boone C, Roth FP (2005) Motifs, themes and thematic maps of an integrated Saccharomyces cerevisiae interaction network. J Biol 4: 6
62. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_uids= 17198971